Ovid Therapeutics to Present at Deutsche Bank’s 43rd Annual Health Care Conference on May 9, 2018
May 02 2018 - 4:05PM
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company
committed to developing medicines that transform the lives of
people with rare neurological disorders, today announced that
management will present a corporate overview at Deutsche Bank’s
43rd Annual Health Care Conference on Wednesday, May 9, 2018 at
10:40 a.m. ET.
A live audio webcast of the presentation can be accessed through
the Events & Presentations section of the company's website at
investors.ovidrx.com. An archived replay of the webcast will be
available on the company's website for two weeks following the live
presentation.
About Ovid TherapeuticsOvid
Therapeutics (NASDAQ:OVID) is a New York-based
biopharmaceutical company using its BoldMedicine™ approach to
develop therapies that transform the lives of patients with rare
neurological disorders. Ovid’s drug candidate, OV101, is currently
in development for the treatment of Angelman syndrome and Fragile X
syndrome. Ovid initiated the Phase 2 STARS trial of OV101
in people with Angelman syndrome in 2017 and completed a Phase 1
trial in adolescents with Angelman syndrome or Fragile X
syndrome. Ovid is also developing OV935 in collaboration
with Takeda Pharmaceutical Company Limited for the
treatment of epileptic encephalopathies and in 2017 initiated a
Phase 1b/2a trial of OV935.
For more information on Ovid, please
visit http://www.ovidrx.com/.
Contacts:
Ovid Therapeutics Inc. Lora Pike Senior Director, Investor
Relations & Public Relationslpike@ovidrx.com
OR
Investors:Burns McClellanSteve Klass,
212-213-0006Sklass@burnsmc.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024